Cargando…

Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104

Lung cancer occurrence and associated mortality ranks top in all countries. Despite the rapid development of targeted and immune therapies, many patients experience relapse within a few years. It is urgent to uncover the mechanisms that drive lung cancer progression and identify novel molecular targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Fan, Li, Ziming, Han, Qing, Cheng, Yirui, Ji, Wenxiang, Yang, Ying, Lu, Shun, Xia, Weiliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176586/ https://www.ncbi.nlm.nih.gov/pubmed/32111983 http://dx.doi.org/10.1038/s41388-020-1227-2

Ejemplares similares

Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
por: Blackwell, Christina, et al.
Publicado: (2016)

FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway
por: Ji, Wenxiang, et al.
Publicado: (2016)

The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach
por: Rezzola, Sara, et al.
Publicado: (2019)

FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas
por: Milton, Christopher I., et al.
Publicado: (2021)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2019)

Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2‐FGFR1 autocrine loop
por: Cen, Mengyuan, et al.
Publicado: (2018)

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
por: Ware, K E, et al.
Publicado: (2013)

The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells
por: LI, SHAORU, et al.
Publicado: (2013)

A miR-327–FGF10–FGFR2-mediated autocrine signaling mechanism controls white fat browning
por: Fischer, Carina, et al.
Publicado: (2017)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

PROJECT ADMINISTRATION AGREEMENT KN2104/TE
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2012)

PROJECT ADMINISTRATION AGREEMENT KN2104/TE
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2012)

AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo
por: Cha, Byung-Hyun, et al.
Publicado: (2021)

FGF19 functions as autocrine growth factor for hepatoblastoma
por: Elzi, David J., et al.
Publicado: (2016)

FGF/FGFR signaling in health and disease
por: Xie, Yangli, et al.
Publicado: (2020)

FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC
por: Zhang, Dan, et al.
Publicado: (2019)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival
por: Tiong, Kai Hung, et al.
Publicado: (2016)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients
por: Tan, Qiang, et al.
Publicado: (2016)

Autocrine FGF1 signaling promotes glucose uptake in adipocytes
por: Nies, Vera J. M., et al.
Publicado: (2022)

Internet-based Prescription of Sildenafil: A 2104-Patient Series
por: Jones, Miles J
Publicado: (2001)

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)

Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells()
por: Ahmed, Abdullah R., et al.
Publicado: (2020)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Osteocyte-Specific Deletion of Fgfr1 Suppresses FGF23
por: Xiao, Zhousheng, et al.
Publicado: (2014)

FGF21 promotes thermogenic gene expression as an autocrine factor in adipocytes
por: Abu-Odeh, Mohammad, et al.
Publicado: (2021)

Suppressive Effect of Autocrine FGF21 on Autophagy-Deficient Hepatic Tumorigenesis
por: Kim, Jinyoung, et al.
Publicado: (2022)

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors
por: Li, Yuan, et al.
Publicado: (2020)

The roles and mechanisms of circular RNAs related to mTOR in cancers
por: Cao, Chunli, et al.
Publicado: (2022)

Sirtuin 1 activator SRT2104 protects Huntington's disease mice
por: Jiang, Mali, et al.
Publicado: (2014)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
por: Raja, Aroosha, et al.
Publicado: (2019)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
por: Harada, Masako, et al.
Publicado: (2015)

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
por: Gatault, Philippe, et al.
Publicado: (2013)

FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy
por: Zhang, Yanshuang, et al.
Publicado: (2022)

The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer
por: Duan, Tinghui, et al.
Publicado: (2021)

(18)F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis
por: Jiang, Yuchen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ah9dr7g21bcr02gvc27cv04ujq